The purpose of this study was to identify regulatory molecule (s) involved in the inflammatory signaling-induced decrease in P-glycoprotein (P-gp) efflux function at the blood-brain barrier (BBB) that may occur in brain diseases. We confirmed that in vivo P-gp efflux activity at the BBB was decreased without any change in P-gp protein expression level in a mouse model of acute inflammation induced by 3 mg/kg lipopolysaccharide. In a human BBB model cell line (human brain capillary endothelial cells; hCMEC/D3), 1-h treatment with 10 ng/mL tumor necrosis factor-a (TNF-a; an inflammatory mediator) rapidly reduced P-gp efflux activity, but had no effect on P-gp protein expression level. To clarify the non-transcriptional mechanism that causes the decrease in intrinsic efflux activity of P-gp in acute inflammation, we applied comprehensive quantitative phosphoproteomics to compare hCMEC/D3 cells treated with TNF-a and vehicle (control). Actin filament-associated protein-1 (AFAP-1), MAPK1, and transcription factor AP-1 (AP-1) were significantly phosphorylated in TNF-a-treated cells, and were selected as candidate proteins. In validation experiments, knockdown of AFAP-1 expression blocked the reduction in P-gp efflux activity by TNF-a treatment, whereas inhibition of MAPK function or knockdown of AP-1 expression did not. Quantitative targeted absolute proteomics revealed that the reduction in P-gp activity by TNF-a did not require any change in P-gp protein expression levels in the plasma membrane. Our results demonstrate that AFAP-1 is a key mediator in the inflammatory signaling-induced, translocation-independent rapid attenuation of P-gp efflux activity in human brain capillary endothelial cells. Keywords: actin filament-associated protein-1, blood-brain barrier, inflammation, P-glycoprotein, phosphorylation, proteomics. J. Neurochem. (2017) 141, 247-262.
therapeutic drugs, P-glycoprotein (P-gp) is the most important drug efflux transporter at the BBB (Tsuji et al. 1992; Kamiie et al. 2008; Uchida et al. 2011 ). However, P-gp transport activity is altered in several CNS diseases (Qosa et al. 2015) . Inflammation is associated with a variety of CNS diseases, including acute brain injury, stroke, epilepsy, multiple sclerosis, motor neuron disease (such as amyotrophic lateral sclerosis), movement disorders, and Alzheimer's disease (Lucas et al. 2006) , and recent evidence suggests that inflammatory mediators such as tumor necrosis factor-a (TNF-a) and sphingosine-1 phosphate (S1P) modulate P-gp function through activation of protein kinase C (PKC) and sphingosine kinase 1 (SphK) signaling (Hartz et al. 2006; Cannon et al. 2012) . These findings suggest that the PKC and SphK signaling pathways would be candidate targets for controlling P-gp function in CNS diseases associated with inflammation. However, PKC is implicated in a wide range of cellular functions, including cell proliferation, differentiation, apoptosis, and angiogenesis, so modulation of PKC is likely to have multiple effects (Mackay and Twelves 2007) . On the other hand, fingolimod, an agonist of S1P receptor, which is involved in downstream signaling of SphK, reduced the basal P-gp transport activity in an animal model, but clinical steadystate fingolimod concentrations are much lower than the concentration used in the animal model, suggesting that it might be difficult to target SphK signaling for modulation of P-gp function in humans (Kalvass et al. 2013) . From these points of view, identification of additional components in the pathway of inflammatory signaling-induced rapid attenuation of P-gp intrinsic efflux activity is important to enable development of effective pharmacotherapy for CNS diseases.
Phosphorylation signaling is thought to be one of the most important P-gp-regulatory mechanisms, because protein kinases such as PKC and SphK are key molecules for modulation of P-gp function (Hartz et al. 2006; Cannon et al. 2012) . Recent advances in phosphoproteomics, combining highly selective phosphopeptide enrichment methods and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) instruments, have enormously facilitated the investigation of phosphorylation signaling. Indeed, this approach has been used to comprehensively quantify changes in the phosphorylation levels of more than 2000 phosphorylation sites in an unbiased way (Sugiyama et al. 2008; Choudhary et al. 2015) . On the other hand, conventional studies of phosphorylation signaling at the BBB have been hampered by the limited availability of specific antibodies to interesting phosphorylation sites, as well as the lack of specific inhibitors/ activators of proteins potentially associated with phosphorylation signaling. Therefore, in this work, we aimed to identify new regulatory molecule(s) involved in the inflammatory signaling-induced decrease in P-gp efflux function using phosphoproteomics technology to compare protein phosphorylation states in human brain capillary endothelial (hCMEC/D3) cells treated with TNF-a and vehicle.
First, we confirmed that the reported decrease in P-gp efflux activity in a mouse model of inflammation (Salkeni et al. 2009; Erickson et al. 2012) was not simply because of the reduced expression of P-gp protein at the BBB, but rather involved a non-transcriptional mechanism(s). Then, we performed comparative phosphoproteomics analysis of hCMEC/D3 cells treated with TNF-a and vehicle to investigate the regulatory proteins involved in inflammatory signaling. Our findings indicate that actin filament-associated protein-1 (AFAP-1) plays a key role in the rapid reduction in intrinsic P-gp activity under inflammatory conditions, and this conclusion is supported by the results of AFAP-1 knockdown experiments.
Materials and methods

Reagents (AE)-Metoprolol (+)-tartrate salt, lipopolysaccharide (LPS)
, and S1P were purchased from Sigma-Aldrich (St. Louis, MO, USA). D-(À)-Mannitol, verapamil hydrochloride, xylitol, and hydrofluoric acid were purchased from Wako Pure Chemicals (Osaka, Japan). PSC833 was purchased from Tocris Bioscience (Bristol, UK). Selumetinib (AZD6244) was purchased from Selleckchem (Houston, TX, USA). Peptide probes were synthesized by Thermo Fisher Scientific (Waltham, MA, USA) or Scrum Inc. (Tokyo, Japan) (> 95% purity). Other reagents were commercial products of analytical grade.
Animals
Adult male ddY mice (25-40 g) were purchased from Japan SLC (Hamamatsu, Japan). All experiments were approved by the Institutional Animal Care and Use Committee in Tohoku University, and were performed in accordance with the guidelines of Tohoku University. To obtain the mouse model of inflammation (LPS-treated mice), 3.0 mg/kg LPS was intraperitoneally administered per mouse at 24 h prior to the experiment. Saline or LPS were alternatively injected to mice to minimize possible administration bias.
Determination of the brain-to-plasma concentration ratio (K p brain ) of a P-gp substrate (verapamil) and membrane-impermeable compound (mannitol) by constant intravenous infusion Determination of the K p brain of verapamil was carried out as described previously (Uchida et al. 2014) . For details, see Method S1.
Preparation of the brain capillary fraction from mice treated with saline and mice treated with 3.0 mg/kg LPS Mouse brain capillaries were isolated as described previously . For details, see Method S2.
Uptake assay to estimate P-gp-mediated [ 3 H]vinblastine efflux activity Uptake assay was performed as described previously (Uchida et al. 2015) . hCMEC/D3 cells were cultured according to Ohtsuki et al. (2013) . hCMEC/D3 cells were seeded at a density 5 9 10 4 cells/well onto Cultrex â Rat Collagen (R&D Systems)-coated 24-well plates. Cells were used for experiments at 6 days after seeding, except for siRNA-transfected cells. The cell surface was washed twice with 500 lL of extracellular fluid (ECF) buffer (122 mM NaCl, 25 mM NaHCO 3 , 3 mM KCl, 0.4 mM K 2 HPO 4 , 10 mM D-glucose, 1.4 mM CaCl 2 , 1.2 mM MgSO 4 Á7H 2 O, 10 mM HEPES, pH 7.4, 300 AE 10 mOsm) and pre-incubated with 200 lL ECF buffer for 55 min at 37°C. To initiate uptake, the pre-incubation buffer was removed and 200 lL ECF buffer containing 50 nM [ 3 H]vinblastine was added. After incubation for 5 min at 37°C, the cell surface was quickly washed four times with 500 lL of ice-cold ECF buffer. When cells were treated with PSC833, TNF-a, S1P or selumetinib, we used ECF buffer containing these compounds during the pre-incubation and uptake procedures. NaOH solution (5 mol/L, 200 lL) was added to the wells and the plates were incubated at 25°C overnight to lyse the cells. HCl solution (5 mol/L. 200 lL) was added for neutralization and the radioactivity in each well was measured by liquid scintillation counting. Protein amount in each well was measured by the Lowry method. Cell-to-medium ratio (C/M ratio) (lL/mg protein) was calculated from the vinblastine concentration in the cell (mol/mg protein) divided by that in the incubation buffer (mol/lL). Efflux activity of P-gp was estimated in terms of C/M ratio according to the theory mentioned below.
Calculation of P-gp efflux activity
In this study, the P-gp efflux transport activity was estimated according to the theory outlined in Scheme 1. To estimate P-gp-specific transport, we calculated P-gp activity from the difference of substrate accumulation in cells in the presence and absence of PSC833, a P-gp inhibitor. The substrate accumulation in the cells is determined in terms of cell-to-medium ratio (C/M ratio), which represents the apparent distribution volume of the substrate determined by the transport rate of P-gp and passive diffusion across the plasma membrane. The C/M ratio is defined as the ratio of the substrate amount in the cell (A cell ) divided by the substrate concentration in the medium (C total, medium ) according to the pharmacokinetic model shown in Scheme 1. It can also be described according to Eq. 4, in terms of the unbound fraction of substrate. The gradient of unbound substrate concentration across the plasma membrane is generated by the ratio between medium-to-cell influx clearance and cell-to-medium efflux clearance. Therefore, the ratio of unbound concentrations in the cell and medium is given by Eq. 5 and Eq. 6 according to the model shown in Scheme 1. In the PSC833 (+) condition, we hypothesized that PS P-gp is equal to zero, because the concentration of PSC833 used in this study is 10-fold higher than the IC 50 of PSC833 for vinblastine transport via human P-gp (Kusunoki et al. 1998) , so that P-gp should be completely inhibited. From the C/M ratios in the presence and absence of PSC833 (Eq. 7 and Eq. 8), we can obtain the R value, which indicates the contribution rate of P-gp to substrate efflux from the cell. The P-gp transport activity (PS P-gp ) is proportional to R-1, as shown in Eq. 10. This finally allows us to estimate the change in P-gp efflux activity in stimulated cells as a percent of the control value from the C/M ratio according to Eq. 12.
In this study, the C/M ratio was obtained experimentally by means of uptake assay. We calculated the change in P-gp efflux activity in stimulated cells by substituting the C/M ratio into Eq. 12.
siRNA transfection of hCMEC/D3 cells Procedures for siRNA transfection of hCMEC/D3 cells are described in Method S3.
Preparation of cytosol fraction and plasma membrane fraction of hCMEC/D3 cells The cytosol fraction and the plasma membrane fraction of hCMEC/ D3 cells were isolated using a Minute Plasma Membrane Protein Isolation Kit (Invent Biotechnologies, Eden Prairie, MN, USA) according to the manufacturer's instructions.
Quantitative targeted absolute proteomics in mouse brain capillaries and hCMEC/D3 cells The absolute protein expression levels of mdr1a, abca1, abca2, abca8a, abca8b, abca9, mdr1b, mrp1, mrp2, mrp3, mrp5, mrp6, bcrp, glut1, glut3, lat1, lat2, 4f2hc, mct1, cd147, oatp14, urat1, fatp1, ent1, pmat, rlip76, insr, lrp1, tfr1, claudin-5, actins Preparation of peptide samples for phosphoproteomic analysis hCMEC/D3 cells were incubated with vehicle or 10 ng/mL TNF-a for 1 h in the ECF buffer or for 6 h in the serum-free culture medium at 37°C. After treatment, cells were washed twice with ice-cold ECF buffer containing PhosSTOP Phosphatase Inhibitor Cocktail (Roche, Basel, Switzerland) at 4°C. The cell suspension was collected and centrifuged at 500 g for 5 min at 4°C. The pellet was immediately resuspended in solubilizer (500 mM Tris-HCl (pH 8.5), 7 M guanidium hydrochloride, and 10 mM EDTA) at 4°C and used as whole-cell lysate. The total protein amount was measured by the bicinchoninic acid method, using Pierce TM bicinchoninic acid Protein Assay Kit (Rockford, IL, USA). The whole-cell lysate of hCMEC/D3 cells was digested with ProteaseMAX (Promega, Madison, Wisconsin, USA), lysC (WAKO), and trypsin (Promega) according to the same protocol described in Method S4. The phosphorylated peptide enrichment was performed using Titansphere â Phos-TiO Kit (GL Science, Tokyo, Japan) according to the manufacturer's instructions. The phosphorylated peptides-enriched fraction was acidified with trifluoroacetic acid and desalted using SDB and GC tips (GL Science) according to the manufacturer's protocol. To increase peptide detection, the phosphorylated peptides collected above were dephosphorylated with hydrofluoric acid as described by Kuyama et al. (2003) . Briefly, the phosphorylated peptides were incubated with 50% hydrofluoric acid for 3 h on ice. The solution containing dephosphorylated peptides was desalted again using SDB and GC tip. The peptide concentration was determined by the Lowry method, and then the dephosphorylated peptides were acidified with formic acid for subsequent nanoLC-MS/MS analysis. x 100
x 100 = -1 In this experiment, it can be assumed that the difference in the peak intensities of dephosphorylated peptides is consistent with the difference in the phosphorylation levels in the peptides between the two conditions before the dephosphorylation step by hydrofluoric acid.
nanoLC-MS/MS conditions and phosphoproteomic analysis
The nanoLC-MS/MS conditions in phosphoproteomic analysis are described in Method S5. Comprehensive phosphoproteomic analysis was performed by means of nanoLC-MS/MS in the informationdependent-acquisition mode as described previously (Nurdin et al. 2016) . Data analysis for peak alignment between different measurements and the calculation of peak intensities were conducted using the two-dimensional image-converted analysis of liquid chromatography-mass spectrometry (2D-ICAL) software package (Mitsui Knowledge Industry Co. Ltd, Tokyo, Japan) with the analytical settings described by Nurdin et al. (2016) . Protein identification was performed using MASCOT software via database searching against the Swiss-Prot Homo sapiens protein database. Peptides with 95% confidence (less than 0.05 pep-expected value calculated by 2D-ICAL software) were defined as 'identified peptides'. Among them, we focused on peptides including serine (S), threonine (T) or tyrosine (Y) in this experiment, because these amino acids are potentially phosphorylatable. Identified peptides that exhibited more than 3-fold difference with statistical significance (p < 0.01, Student's t-test) between the two groups were finally selected and are listed in Tables S2 and S3 .
Statistical analysis
All statistical analyses were performed under the null hypothesis that means of the compared groups were equal. Comparison between two groups was performed by an unpaired two-tailed Student's t-test (equal variance) or Welch's test (unequal variance) according to the result of the F test. For more than two groups, a one-way analysis of variance (ANOVA) followed by Bonferronicorrected Student's t-tests were performed to determine the statistical significance between datasets. To evaluate the effects of two categorical variables, a two-way repeated-measures ANOVA was performed and post hoc comparisons were carried out using Bonferroni-corrected Student's t-tests for multiple comparisons. If a p-value was less than 0.05, the difference was considered as statistically significant and the null hypothesis was rejected.
No formal power calculation was performed to estimate the required sample size, as a sample size of 3-4 is typically used in mouse studies to examine changes in K p brain of verapamil and protein expression levels of BBB transporters (Uchida et al. 2014) , as well as in uptake assay and QTAP analysis using hCMEC/D3 cells (Uchida et al. 2015) .
Results
Effect of LPS on the distributions of verapamil and mannitol to mouse brain
The distribution of verapamil, a typical P-gp substrate, to the brain of LPS (3 mg/kg)-treated mice after 24 h was significantly (1.74-fold) greater than that in saline-treated control mice, in terms of the K p brain values (Table 1) . No significant difference in K p brain value of mannitol, a membraneimpermeable compound, was observed between LPS-and saline-treated mice ( Table 1 ), confirming that the tight junctions of the BBB were not impaired by LPS treatment. These results suggested that LPS decreased the efflux function of P-gp at the BBB without causing loss of integrity of the BBB.
Effect of LPS on protein expression levels of transport proteins and tight junction protein in mouse brain capillaries The QTAP technique was applied to brain capillaries isolated from LPS-and saline-treated mice to clarify whether the protein expression levels of transport proteins and tight junction protein at the BBB were changed at 24 h after LPS administration (Table 2) . No significant difference in P-gp protein expression level was observed between the LPS-and Scheme 1 Theory for estimation of the change in P-gp efflux activity between control and stimulated cells from the cell-to-medium ratio (C/M ratio) in the absence (À) and in the presence (+) of PSC833. In the pharmacokinetic model illustrated in Scheme 1, C total, cell , C b, cell , and C u, cell represent the total, bound, and unbound concentrations of the substrate (mol/lL) in the cell, respectively. C total, medium and C u, medium represent the total and unbound concentrations of the substrate (mol/lL) in the medium. A cell represents the amount of the substrate (mol/mg protein) in the cell. V cell represents the volume of the cell (lL/mg protein). PS passive, inf , PS passive, eff , and PS P-gp represent the PS products for the medium-to-cell influx clearance by passive diffusion, cell-to-medium efflux clearance by passive diffusion, and P-gp-mediated cell-to-medium efflux clearance, respectively. (a) C/M ratio is defined as the ratio of the total amount of the substrate in the cell (A cell ) and the total substrate concentration in the medium (C total, medium ) (Eq. 1). According to the pharmacokinetic model, C/M ratio is given by Eq. 2, because A cell is determined by C total, cell multiplied by V cell . Furthermore, the substrate was incubated in protein-free medium (ECF buffer), so C total, medium is equal to C u, medium . C total, cell can be replaced with C u, cell and unbound fraction (fu) using Eq. 3. Therefore, C/M ratio can be obtained according to Eq. 4. (b) The gradient of the unbound substrate concentration across the plasma membrane is generated by the ratio between medium-to-cell influx clearance and cell-tomedium efflux clearance. Therefore, the ratio between unbound concentrations in the cells and in the medium can be described by Eq. 5 in the absence of PSC833 (À) and Eq. 6 in the presence of PSC833 (+) using PS products according to the pharmacokinetic model. (c) Based on Eq. 4, Eq. 5, and Eq. 6 shown in (a) and (b), C/M ratio PSC833 (À) , and C/M ratio PSC833 (+) are given by Eq. 7 and Eq. 8, respectively. R indicates the contribution rate of P-gp to substrate efflux from the cell, because PSC833 is an inhibitor of P-gp and completely inhibits P-gp transport at the concentration used in this study. Finally, PS P-gp can be obtained using PS passive, eff and R, as shown in Eq. 10, which was rearranged from Eq. 9. (d) P-gp activity in stimulated cells is calculated by comparing PS P-gp in the control with PS P-gp in stimulated cells (Eq. 11). P-gp activity in stimulated cells (percent of control) is obtained using the C/M ratios, according to Eq. 12.
saline-treated mice. Thus, the decreased efflux function per P-gp protein at the BBB at 24 h after 3 mg/kg LPS administration (Table 1) was not because of decreased P-gp protein expression. Protein expression of claudin-5, a component of tight junctions at the BBB, was also unchanged. Among other transport proteins and related proteins, only mct1, cd147, oatp1a4, and oat3 showed significant differences in protein expression level.
Effect of TNF-a on P-gp-mediated vinblastine efflux and P-gp protein expression level in hCMEC/D3 cells To investigate whether inflammation is associated with decreased P-gp transport function not only in LPS-treated mice, but also in a human BBB model, we used hCMEC/D3 cells treated with TNF-a, a major inflammatory mediator. Short-term (1 h) TNF-a treatment was tested to eliminate the possibility that the P-gp protein expression level might be changed by TNF-a within the experimental timeframe.
The C/M ratio of vinblastine was increased 1.90-and 1.52-fold by PSC833 treatment under control and TNF-a-treated conditions, respectively (Fig. 1a) . According to Scheme 1, P-gp efflux activity was estimated from the difference of C/M ratio in the presence and absence of PSC833. P-gp activity was significantly reduced by 42.3% in TNF-a-treated hCMEC/D3 cells (Fig. 1b) . In contrast, the protein expression levels of P-gp and Na + /K + ATPase in whole-cell lysate of hCMEC/D3 were not significantly changed (Fig. 1c) . These results suggest that TNF-a rapidly decreased P-gp transport activity without altering its protein expression level in human brain capillary endothelial cells.
The C/M ratio of vinblastine was approximately 79-fold higher than 2 lL/mg protein which is the intracellular volume estimated from the steady-state distribution volume of 3-O-methyl-D-glucose in the TR-BBB cell line (Hosoya et al. 2000) . This suggested a very high uptake which is perhaps not solely caused by diffusion. Incidentally, the distribution volume of vinblastine in the cells, which was calculated from the C/M ratio in PSC833 (À) under control conditions shown in Fig. 1(a) (157 lL/mg protein) multiplied by the amount of total protein in each well (approximately 0.05 mg protein/well), was 3.9% of the volume of the extracellular medium (200 lL).
Identification of candidate proteins phosphorylated in response to TNF-a treatment of hCMEC/D3 cells We searched for molecules whose phosphorylation level in hCMEC/D3 cells was altered by 1-h TNF-a treatment, by employing a comprehensive comparative phosphoproteomic approach. An earlier study has revealed that TNF-a-induced rapid reduction in P-gp efflux activity is reversible (Bauer et al. 2007) . From 1 to 3-h, treatment with TNF-a reduced Pgp efflux activity, while over 3 h treatment with TNF-a increased P-gp efflux activity up to 6 h. Accordingly, we selected molecules that were more phosphorylated by 1-h TNF-a treatment rather than 6-h TNF-a treatment.
We found 25 proteins (27 peptides) whose phosphorylation levels were significantly increased by 1-h TNF-a treatment. On the other hand, we found 30 proteins (38 peptides) that were significantly phosphorylated in the case of 6-h TNF-a treatment. On the basis of these results, we selected three proteins, AFAP-1, MAPK1, and transcription factor AP-1 (AP-1) (Table 3) , as candidate regulators of P-gp transport activity for the reasons described below.
AFAP-1 phosphorylation was increased 3.96-fold by 1-h TNF-a treatment, but was not detected after 6-h treatment. It was reported that activation of PKC promotes the crosslinking of actin filaments in AFAP-1 over-expressing HEK293 cells (Qian et al. 2002) . Since PKC is a key molecule in the inflammatory signaling responsible for the rapid reduction in P-gp efflux activity at the BBB (Hartz Adult male ddY mice were intraperitoneally injected with 3 mg/kg LPS dissolved in isotonic saline (LPS) or saline (Control). After 24 h, mice received constant intravenous infusion of verapamil to the jugular vein at a rate of 500 nmol/h/kg following 1-min rapid infusion (500 nmol/min/kg).
Mannitol is a membrane-impermeable compound used to check the integrity of the BBB. Mice received constant intravenous infusion of mannitol at a rate of 2 mmol/h/kg without rapid infusion. The plasma and brain concentrations were measured at 80 min, and the brain-to-plasma concentration ratio (K p brain ) values were individually calculated by dividing the brain concentration by the plasma concentration in each mouse. Each value represents the mean AE SEM (n = 3-4). An average of the K p brain values was determined from 3 to 4 K p brain values calculated from 3 to 4 mice. **p < 0.01 and N.S. (p > 0.05), significantly and not significantly different from the K p brain value in control group, respectively (Student's t-test).
et al. 2006), it is plausible that AFAP-1 plays a role in this pathway. MAPK phosphorylation was increased 3.03-fold in 1-h TNF-a treatment, but was not detected in the case of 6-h treatment. Since PKC activates the MAPK pathway in MAPK-over-expressing COS1 cells (Ueda et al. 1996) , we selected MAPK as another candidate.
As for AP-1, the 1-h TNF-a treatment increased the phosphorylation levels of two AP-1 peptides by more than 3-fold, though only one of these two peptides was less highly Brain capillary-enriched fractions were prepared at 24 h after intraperitoneal injection of adult male ddY mice with 3 mg/kg LPS (LPS) or saline (Control). The fraction was digested with trypsin and the digests were subjected to LC-MS/MS together with internal standard peptides. Each value represents the mean AE SEM (the number of samples processed and injected = 3-4, and the number of SRM/MRM transitions = 3-4). The data of mrp4, pgt, oatp1a4, and oat3 were taken from Akanuma et al. (2011) . The protein expression levels of the other proteins were determined in this study. *p < 0.05 and **p < 0.01, significantly different from the control group. LQ, limit of quantification. ULQ, under the limit of quantification.
phosphorylated in the case of 6-h TNF-a treatment (NSDLLTSPDVGLLK, less than 3-fold). AP-1 is one of the immediate early genes which are the first genes altered to adjust to acute environmental changes (Svenningsson et al. 1995; Pennypacker 1998) . Yarilina et al. (2011) found that TNF-a rapidly induced nuclear expression of AP-1 protein after a 1-h TNF-a stimulation in human macrophages, but no AP-1 was detected after this although AP-1 reemerged after 24-48-h TNF-a treatment (Yarilina et al. 2011) . Previous studies investigating the regulatory mechanism of P-gp by AP-1 as a transcriptional regulator of P-gp only focused on the chronic phase regulation (Hartz et al. 2008; Katayama et al. 2014) . So, we selected AP-1 as the third candidate to examine the effect of AP-1 as an immediate early gene on the Fig. 1 Effect of inflammatory mediator tumor necrosis factor-a (TNF-a) on P-gp efflux activity and protein expression level in hCMEC/D3 cells. (a) hCMEC/D3 cells were pre-incubated in extracellular fluid (ECF) buffer containing 10 ng/mL TNF-a (TNF-a group) or vehicle (Control group) for 55 min at 37°C, and then the cellular uptake of the P-gp substrate vinblastine was measured for 5 min, also in the presence of 10 ng/mL TNF-a for the TNF-a group or vehicle for the control group (the total time of TNF-a or vehicle treatment is 60 min). The cellular uptake of vinblastine by hCMEC/D3 cells for 5 min was measured at 37°C in ECF buffer containing 50 nM vinblastine in the presence (+) or absence (À) of 10 lM PSC833, an inhibitor of P-gp. To effectively inhibit P-gp efflux activity, PSC833 was not only present during the 5-min uptake of vinblastine but also during the 55 min pre-incubation with hCMEC/D3 cells before the start of the uptake experiment (total time of PSC833 treatment is thus 60 min). The cellular uptake was expressed as the cell-to-medium ratio as described in Materials and Methods. Each column represents mean AE SEM (n = 3). (b) Based on the data of (a), P-gp efflux activity was calculated from the cell-tomedium ratio in the absence and presence of PSC833 according to Eq. 12 in Materials and Methods. Each column represents mean AE SEM (n = 3). *p < 0.05, significant difference between two groups (Student's t-test). (c) Protein expression levels of P-gp and Na acute reduction in P-gp efflux activity in inflammatory signaling.
MAPK and AP-1 are not involved in the rapid TNFa-induced decrease in P-gp efflux activity If activation of candidate proteins is involved in the rapid reduction in P-gp activity in response to inflammatory signaling, the decrease in P-gp activity by TNF-a should be blocked by inhibitors of these proteins. Therefore, we first examined the effects of MAPK and AP-1 inhibitors in hCMEC/D3 cells. Selumetinib, a MAPK/ERK kinase inhibitor, was used to inhibit the MAPK pathway. According to Scheme 1, P-gp efflux activity was estimated from the difference in C/M ratio shown in Fig. 2(a) in the presence and absence of PSC833. In the vehicle group, P-gp activity was significantly reduced by TNF-a treatment for 1 h (Fig. 2b) . However, TNF-a also significantly reduced the P-gp activity in the selumetinib group, suggesting that MAPK is not involved in the rapid reduction in P-gp efflux activity by TNF-a.
For inhibition of AP-1, we used AP-1 siRNA to knock down AP-1 in hCMEC/D3 cells. According to Scheme 1, Pgp efflux activity was estimated from the difference in the C/ M ratio shown in Fig. 2(c) in the presence and absence of PSC833. Because AP-1 is a transcriptional regulator of P-gp (Hartz et al. 2008; Katayama et al. 2014) , not only TNF-a but also AP-1 siRNA could reduce P-gp efflux activity. Accordingly, we performed two-way ANOVA to evaluate the two categorical variables, the effect of TNF-a and AP-1 siRNA on P-gp efflux activity. A two-way ANOVA showed significant effects for TNF-a (p < 0.005), AP-1 siRNA (p < 0.005), but not for the interaction (p = 0.883). Post hoc Bonferroni-corrected Student's t-tests indicated that there is no reduction in the TNF-a effect following AP-1 siRNA treatment (Fig. 2d) . This result suggested that AP-1 is not involved in the rapid reduction in P-gp activity by TNF-a.
AFAP-1 is involved in the rapid reduction in P-gp efflux activity by TNF-a and S1P According to Scheme 1, P-gp efflux activity was estimated from the difference in C/M ratio shown in Fig. 3(a) in the presence and absence of PSC833. In the negative control siRNA group, TNF-a significantly reduced P-gp activity (Fig. 3b) . However, the reduction in P-gp activity not only by 10 ng/mL, but also by 100 ng/mL TNF-a treatment was blocked in the AFAP-1 siRNA group. These results suggest that AFAP-1 is an essential component of the molecular signaling involved in the rapid reduction in P-gp activity by TNF-a in hCMEC/D3 cells.
Among the molecules so far identified in the inflammatory signaling pathway regulating the P-gp efflux activity at the BBB, S1P, and its receptor are located downstream of PKC activation (Cannon et al. 2012 ). To investigate whether or not AFAP-1 is located downstream of S1P, we examined whether the reduction in P-gp efflux activity by S1P is suppressed by knockdown of AFAP-1 expression. According to Scheme 1, P-gp efflux activity was estimated from differences in the C/M ratio shown in Fig. 3(c) in the presence and absence of PSC833. Indeed, the AFAP-1 siRNA treatment attenuated the reduction in P-gp efflux activity by S1P (p = 0.0990, Fig. 3d ), supporting the idea that AFAP-1 is located downstream of S1P. hCMEC/D3 cells were treated with 10 ng/mL tumor necrosis factor-a (TNF-a) or vehicle (Control) for 1 or 6 h, and then whole-cell lysates were digested with lysyl endopeptidase and trypsin. The phosphorylated peptides in the digests were enriched by the HAMMOC method. To increase the sensitivity of LC-MS/MS detection, the phosphorylated peptides were dephosphorylated by incubation with hydrofluoric acid. Finally, dephosphorylated peptides were measured by nanoLC-MS/MS in the shotgun mode (information-dependent acquisition mode) in triplicate experiments. The peak intensities of the precursor ions of the dephosphorylated peptides were comprehensively compared between 10 ng/mL TNF-a-and vehicle-treated (Control) conditions using 2D-ICAL software. Among the identified proteins, proteins with a statistically significant difference were selected as described in Materials and Method and listed in Table S2 (1 h treatment) and 3 (6 h treatment). In this experiment, it is assumed that the difference in the peak intensities of dephosphorylated peptides detected is consistent with the difference in the phosphorylation levels in the peptides between the two conditions before the dephosphorylation step by hydrofluoric acid (possible phosphorylation sites are indicated with underlines). Among the proteins listed in Tables S2 and S3 , we selected the three listed in this table as candidate proteins potentially involved in regulating P-gp efflux function because of the reasons mentioned in the Results section.
a Neither the indicated peptides, nor any other peptides from AFAP-1 and MAPK were detected at all.
Effect of TNF-a on protein expression levels of AFAP-1 and P-gp in cytosol fraction, plasma membrane fraction and whole-cell lysate of hCMEC/D3 cells One of the possible mechanisms of the TNF-a-mediated rapid reduction in P-gp efflux activity is because of increased expression of AFAP-1 and reduced expression of plasma membrane P-gp. Thus, we applied the QTAP technique to clarify whether the protein expression levels of AFAP-1 and P-gp are changed by TNF-a treatment at the sites of their functional activity (in the cytosol fraction and plasma membrane fraction, respectively). Their protein expression levels were also measured in whole-cell lysate. AFAP-1 protein was detected only in the cytosol fraction (Table 4) . No significant difference was observed in the protein expression levels of AFAP-1 between control and TNF-a-treated cells. Also, it was confirmed that the protein expression level of AFAP-1 was knocked down by more than 67.1% by transfection of AFAP-1 siRNA. hCMEC/D3 cells were incubated with vehicle or 1 lM selumetinib during both 55-min pre-incubation and 5-min vinblastine uptake (total time for vehicle or selumetinib treatment: 60 min). Each column represents the mean AE SEM (n = 3). *p < 0.05, significant difference between two groups (Student's t-test). (c and d) The effect of AP-1 siRNA on the TNF-a-mediated attenuation of P-gp efflux activity. Each column represents the mean AE SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.005, significant difference between two groups (Bonferroni-corrected Student's t-test after two-way repeated-measures ANOVA).
No significant difference was observed in the protein expression levels of P-gp between control and TNF-a-treated cells, either in the plasma membrane fraction or in whole-cell lysate.
Discussion
Our results show for the first time that AFAP-1 plays an essential role in the rapid reduction in intrinsic P-gp transport activity induced by TNF-a in human brain capillary endothelial cells. We confirmed that the reported reduction in the efflux activity of P-gp was without any change in P-gp protein expression level at the in vivo BBB in the early phase inflammation (Salkeni et al. 2009; Erickson et al. 2012) . A non-transcriptional reduction in P-gp activity was also found in hCMEC/D3 cells. Further analysis using TNF-a-treated hCMEC/D3 cells showed that the rapid reduction in P-gp activity did not involve any change in P-gp protein expression levels or translocation. Phosphoproteomic analysis showed a rapid increase in AFAP-1 phosphorylation level. The loss of function using siRNA against AFAP-1 revealed AFAP-1 is involved in the rapid reduction in P-gp activity in TNF-a-treated hCMEC/D3 cells.
Previously, the LPS effect on P-gp function and protein expression level at the BBB has been separately discussed in two independent reports (Salkeni et al. 2009; Erickson et al. 2012) . The type of inflammation may vary according to the pro-inflammatory compound injected, the dose and the site of injection (Fernandez et al. 2004) . Inflammation produced in animal models do not always give similar results, so an analysis investigating the P-gp efflux activity and its protein expression level under the same inflammatory condition is needed to understand the effect of LPS on P-gp function. In this study, although we cannot exclude the possibility that several other pharmacokinetic parameters, such as unbound protein in the brain and plasma being able to influence the uptake of verapamil, we confirmed the reported reduction in P-gp function and no change in P-gp protein expression level at the BBB in 
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Cell to medium ratio (μL/mg protein) Fig. 3 Attenuation of P-gp efflux activity by tumor necrosis factor-a (TNF-a) (a and b) or sphingosine-1-phosphate (S1P) (c and d) was blocked by knockdown of actin filament-associated protein-1 (AFAP-1). The uptake of vinblastine by hCMEC/D3 cells was conducted under the same experimental conditions as in (a), but with two different TNFa concentrations (10 or 100 ng/mL) (a and b) or 1 lM S1P instead of TNF-a (c and d). The P-gp efflux activity was determined from the difference in substrate accumulation in cells in the presence and absence of PSC833, an inhibitor of P-gp, according to Eq. 12 in Materials and Methods. Each column represents the mean AE SEM (n = 3-6). *p < 0.05, **p < 0.001, and ***p < 0.005, significant difference between two groups. N.S., no significant difference between the two groups (p > 0.05) (Bonferroni-corrected Student's t-test for b and Student's t-test for d).
LPS-treated mice under the same experimental conditions (Tables 1 and 2) . Knockdown of AFAP-1 almost completely blocked the reduction in P-gp activity by TNF-a (Fig. 3a) , confirming that AFAP-1 is essential for the rapid reduction in P-gp activity. Previously, acute inflammatory signaling involving P-gp was explored using isolated rat brain capillaries. Hartz et al. (2006) showed that TNF-a activates through TNF receptor 1 to release endothelin-1. Endothelin-1, in turn, activates an ET B receptor, nitric oxide synthase, and PKC, causing rapid but reversible loss in P-glycoprotein transport function. Also, Cannon et al. (2012) found that S1P and its receptor are located downstream of PKC activation (Cannon et al. 2012) . Here, we have shown that knockdown of AFAP-1 suppressed the reduction in P-gp activity by S1P (Fig. 3d) . If the S1P-mediated signaling is also downstream of TNF-a signaling in the human BBB as well as the rodent BBB, our finding indicates that AFAP-1 is located downstream of S1P in the signaling pathway that modulates P-gp efflux activity under inflammatory conditions.
In this study, P-gp efflux activity was determined from the increase in the C/M ratio of vinblastine in the presence of PSC833. Evidence that multidrug resistance-associated proteins (MRPs), especially MRP1, MRP2, and MRP7, are involved in vinblastine efflux has been reported previously (Chen and Tiwari 2011) . Thus, the effect of MRPs-mediated vinblastine efflux on the increase in the C/M ratio by PSC833 should be taken into consideration. The protein expression levels of MRPs in hCMEC/D3 cells only involved MRP1 and MRP4 among the 13 MRP family members (MRP1-MRP13) . As high concentrations of PSC833 are known to inhibit MRP1 (Leier et al. 1994) , the inhibition of MRP1-mediated vinblastine transport by PSC833 could affect the increase in the C/M ratio in the presence of PSC833. Although we cannot rule out the possibility that the other MRPs are involved in the change in C/M ratio by PSC833, we assumed the contribution of MRP1, which was suggested by previous reports to be involved in the elimination of vinblastine from hCMEC/D3 cells together with P-gp. The detailed derivation process is shown in Information S1. Finally, we assumed that the contribution to the increase in C/M ratio of vinblastine by PSC833 was 1.92-6.90% for MRP1 and 93.1-98.1% for P-gp. Therefore, the contribution of MRP1 efflux to the determination of P-gp efflux activity would be very low.
The C/M ratio of vinblastine was approximately 79-fold higher than 2 lL/mg protein, which is the estimated intracellular volume in the TR-BBB cell line (Hosoya et al. 2000) (Fig. 1a) . This suggested a very high uptake, indicating that some mechanism(s) other than diffusion may also be involved. One possible explanation is that hydrophobic weakly basic drugs such as vinblastine are ionized at lysosomal pH (pH 4-5), and consequently they are sequestered and trapped in lysosomes (Zhitomirsky and Assaraf 2015) . In the case of sunitinib, which is highly accumulated in lysosomes, the intracellular concentration is approximately 1000-fold higher in renal and colon cancer cells than the concentration in the conditioned medium (Gotink et al. 2011) . Thus, the potent accumulation of vinblastine in the cells that we observed may be because of lysosomal accumulation. On the other hand, it was reported that 4-h TNF-a exposure increased the lysosomal pH in human histiocytic lymphoma cells (Nilsson et al. 2003) . Such an increase in lysosomal pH would decrease the proportion of drugs in the cationic state and thus reduce lysosomal accumulation. In this study, the most profound change caused by TNF-a was to impact the C/M ratio in the presence of PSC833 (PSC833-independent efflux), but TNFa also had a minimal impact on the C/M ratio in the absence of PSC833 (PSC833-dependent and -independent efflux). Thus, it could be considered that TNF-a exposure reduced lysosomal accumulation of vinblastine in both the presence and absence of PSC833, but in the absence of PSC833, TNF-a simultaneously increased vinblastine accumulation by reducing P-gp efflux activity, so that the change in C/M ratio was minimal. Therefore, we cannot exclude the possibility that TNF-a affected the lysosomal accumulation of vinblastine, but PSC833-dependent efflux could mainly reflect the change in P-gp efflux activity in hCMEC/D3 cells. After the uptake assay, the vinblastine concentration in the medium was considerably lower than the prepared concentration (Table S4) . Furthermore, the vinblastine concentration in the medium was 2-fold lower in the absence of PSC833. We think this might be because of non-specific interaction of vinblastine with plasticware during sample preparation and uptake assay. It was reported that vinblastine concentration was reduced by 44% after 48-h incubation in a plastic container, although in that case the initial concentration was approximately 3.7 lM (74-fold higher than in this study) (McElnay et al. 1988) . Therefore, a possible interpretation of our observations is that the high concentration of PSC833 partially inhibited the non-specific interaction of the vinblastine with plasticware during sample preparation and uptake assay.
The key data supporting the absence of cell surface trafficking of P-gp is based on proteomic analysis on cytosolic and membrane samples obtained using a commercial plasma membrane isolation kit (Minute Plasma Membrane Protein Isolation kit). Wen et al. (2013) used this preparation protocol for investigating the intracellular trafficking of BK-a to the plasma membrane. They confirmed BK-a trafficking by both immunohistochemical analysis and increased expression of BK-a in the plasma membrane fraction prepared using the Minute Plasma Membrane Protein Isolation kit (Wen et al. 2013) . This suggests that the change in the protein expression level in the plasma membrane fraction obtained using the Minute Plasma Membrane Isolation Kit would be correlated with the changes examined by other methods for investigating intracellular trafficking. For example, our previous reports using the plasma membrane fraction of hCMEC/D3 cells prepared by a sucrose density gradient centrifugation method showed that the protein expression level of Na + /K + ATPase is increased 4.3-fold in the plasma membrane fraction compared with that in the whole-cell lysate . In this study, the protein expression level of Na + /K + ATPase in the plasma membrane fraction was 4.1-fold higher than that in the whole-cell lysate. From these results, no change in the P-gp protein expression level in the plasma membrane fraction prepared using the Minute Plasma Membrane Protein Isolation kit could be interpreted as there being no trafficking in plasma membrane P-gp by TNF-a exposure. Quantitative targeted proteomics revealed that AFAP-1 was detected only in the cytosol fraction, whereas P-gp was localized mostly in the plasma membrane fraction. We cannot rule out the possibility that below the detection limit of AFAP-1 directly interact with P-gp, but the low distribution of AFAP-1 in the plasma membrane fraction indicates that AFAP-1 may not directly regulate P-gp function at the plasma membrane. Recently, Tome et al. (2015) identified P-gp-binding partners in rat brain microvessels using a comprehensive proteomics approach (Tome et al. 2015) . Among the P-gp binding proteins they found, protein disulfide isomerase (PDI) was reported to interact with b-actin, a component of actin filament, in a human megakaryoblastic leukemia cell line (Sobierajska et al. 2014) . Cell surface expression of PDI is inhibited by actin filament disruption (Wan et al. 2012 ) and because AFAP-1 is necessary to form the actin stress fibers (Dorfleutner et al. 2007) , these findings raise the possibility that AFAP-1 is associated with the interaction between P-gp and PDI through the actin filaments. The primary role of PDI is introducing disulfide bonds into proteins (Wilkinson and Gilbert 2004) . Interestingly, the ATPase activity of purified wild-type P-gp was activated by dithiothreitol, which can reduce disulfide bonds (Urbatsch et al. 2001) . This may indicate that the formation of disulfide bonds in human wildtype P-gp keeps the ATPase activity low. Based on these findings, the recovery of the TNF-a-mediated reduction in Pgp efflux activity in AFAP-1 knock-downed hCMEC/D3 cells would be because of the reduced interaction of PDI and P-gp. Further study investigating the interaction of AFAP-1 (or phosphorylated AFAP-1) and PDI using activators of AFAP-1 phosphorylation (phorbol ester derivatives) might help us understand the regulatory mechanism of the rapid reduction in intrinsic P-gp transport activity in inflammatory signaling.
Previous studies on the regulatory mechanisms of P-gp function at the BBB have been carried out using mainly rodent samples and rodents, such as isolated rat brain microvessels or mice treated with signaling molecule inhibitor/activator (Hartz et al. 2006; Salkeni et al. 2009; Cannon et al. 2012) . In contrast, in this study, we used a human BBB cell line, and found that AFAP-1 is involved in the rapid reduction in P-gp function associated with inflammatory signaling. Protein expression of AFAP-1 in the human brain microvasculature has been confirmed immunohistochemically (Snyder et al. 2011) . Therefore, AFAP-1 may be a candidate target to control the P-gp efflux function at the human BBB in CNS diseases associated with inflammation.
This study examined the short-term effects of TNF-a (1 h) in an in vitro model, whereas the inflammatory response in vivo was examined after 24-h exposure. In in vivo mice, LPS reduced P-gp efflux activity from 18 h after LPS administration up to 36 h (Salkeni et al. 2009 ). However, in isolated rat brain capillaries, TNF-a reduced P-gp efflux activity from 1 h after TNF-a exposure up to 3 h, and then increased P-gp efflux activity from 3 up to 6 h after TNF-a exposure (Bauer et al. 2007 ). On the basis of these findings, we set the different time points when P-gp efflux activity would be reduced in vivo and in vitro. However, the regulatory mechanism clarified by the in vitro study using 1-h TNF-a treatment cannot be directly extrapolated to the reduction in P-gp activity in the in vivo inflammation study. It is well-known that LPS preferentially induces not only TNF-a but also interleukin-1b (IL-1b), IL-2, IL-6, and Interferon-c release. Differences in the pro-inflammatory cytokine release over different periods cause a complicated network of P-gp signaling (Fernandez et al. 2004) . Transcriptional factors such as NF-kB, NF-IL6, cAMP-response element binding protein/ATF, AP-1, and STAT are involved in the control of the mRNA expression of genes during the acute phase response (Akira 1997) . Regarding another possible mechanism, Matsumoto et al. (2012) suggested that LPS-activated microglia reduced P-gp function through an NADPH oxidase-dependent pathway without affecting P-gp transcription in rat brain endothelial cells (Matsumoto et al. 2012) . Therefore, AFAP-1 expression is one of the factor involved in reducing P-gp efflux activity in inflammatory singling, but further study is needed to understand the extent to which AFAP-1 contributes to the reduction in P-gp efflux activity in in vivo inflammation.
In conclusion, our findings obtained by means of a phosphoproteomic approach indicate that AFAP-1 is a key molecule in the TNF-a-mediated inflammatory signaling pathway that leads to a rapid decrease in P-gp intrinsic transport activity without its translocation in human brain capillary endothelial cells.
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